Skip to content

A Prospective Observational Study on Early Clinical Characteristics, Intervention Strategies and Short-term Prognosis in Patients with Hyperlipidemic Pancreatitis

A Prospective Observational Study on Early Clinical Characteristics, Intervention Strategies and Short-term Prognosis in Patients with Hyperlipidemic Pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600130218
Enrollment
Unknown
Registered
2026-08-17
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemic Acute Pancreatitis

Interventions

Sponsors

Ningbo No.2 Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for hyperlipidemic acute pancreatitis (HLAP): a. Satisfy the diagnosis of acute pancreatitis (acute abdominal pain plus serum amylase/lipase >= 3 times the upper limit of normal, or abdominal CT showing pancreatitis-associated changes); b. Serum triglyceride (TG) >= 11.3 mmol/L, or serum chylomicronemia with TG ranging from 5.65 to 11.3 mmol/L, and biliary, alcoholic and other etiologies are excluded. 2. Aged 18 to 80 years old (inclusive). 3. Patients admitted to the Emergency Intensive Care Unit (EICU) of our hospital within 24 hours after onset. 4. Written informed consent signed by the patient or their legal representative.

Exclusion criteria

Exclusion criteria: 1. Pancreatitis caused by combined other etiologies (e.g., cholelithiasis, alcoholic intoxication, drug-induced pancreatitis, traumatic pancreatitis, etc.). 2. Previous history of chronic pancreatitis or pancreatic surgery. 3. Complicated with advanced malignant tumors, severe immunodeficiency diseases, end-stage hepatic and renal failure. 4. Pregnant or lactating women. 5. Expected hospital stay less than 72 hours, or extremely high risk of loss to follow-up during follow-up period (e.g., no stable contact information). 6. Subjects who refuse to participate in this study or cannot cooperate to complete follow-up.

Design outcomes

Primary

MeasureTime frame
blood lipid parameters;death;length of ICU stay;total hospital stay;

Secondary

MeasureTime frame
Organ failure (cardiac, pulmonary and renal);The 3-month readmission rate and case-fatality rate after hospital discharge were recorded.;rate of pancreatic necrosis;Incidence of infectious complications (pancreatic abscess, sepsis);

Countries

China

Contacts

Public ContactQi Zheng

Ningbo No.2 Hospital

oktellu@hotmail.com+86 574 83870361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026